Myers Ronald E, Advani Shailesh M, Myers Pamela, Selvan Preethi, Garber Gregory, Worster Brooke, Flomenberg Neal, Chapman Andrew, Zinner Ralph
Division of Population Science, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Data Scientist, Terasaki Institute of Biomedical Innovation, 1018 Westwood Blvd, Los Angeles, CA 90024, USA.
J Pers Med. 2021 Oct 1;11(10):998. doi: 10.3390/jpm11100998.
Few treatment decision support interventions (DSIs) are available to engage patients diagnosed with late-stage non-small cell lung cancer (NSCLC) in treatment shared decision making (SDM). We designed a novel DSI that includes care plan cards and a companion patient preference clarification tool to assist in shared decision making. The cards answer common patient questions about treatment options (chemotherapy, chemotherapy plus immunotherapy, targeted therapy, immunotherapy, clinical trial participation, and supportive care). The form elicits patient treatment preference. We then conducted interviews with clinicians and patients to obtain feedback on the DSI. We also trained oncology nurse educators to implement the prototype. Finally, we pilot tested the DSI among five patients with NSCLC at the beginning of an office visit scheduled to discuss treatment with an oncologist. Analyses of pilot study baseline and exit survey data showed that DSI use was associated with increased patient awareness of the alternatives' treatment options and benefits/risks. In contrast, patient concern about treatment costs and uncertainty in treatment decision making decreased. All patients expressed a treatment preference. Future randomized controlled trials are needed to assess DSI implementation feasibility and efficacy in clinical care.
几乎没有治疗决策支持干预措施(DSIs)可用于让被诊断为晚期非小细胞肺癌(NSCLC)的患者参与治疗共同决策(SDM)。我们设计了一种新型DSI,其中包括护理计划卡和配套的患者偏好澄清工具,以协助进行共同决策。这些卡片回答了患者关于治疗选择(化疗、化疗加免疫疗法、靶向疗法、免疫疗法、参与临床试验和支持性护理)的常见问题。该表格引出患者的治疗偏好。然后,我们对临床医生和患者进行了访谈,以获取他们对DSI的反馈。我们还培训了肿瘤护理教育工作者来实施该原型。最后,我们在安排与肿瘤学家讨论治疗方案的门诊开始时,对五名NSCLC患者进行了DSI的试点测试。对试点研究基线和退出调查数据的分析表明,使用DSI与患者对替代治疗方案及其益处/风险的认识增加有关。相比之下,患者对治疗费用的担忧以及治疗决策中的不确定性有所降低。所有患者都表达了治疗偏好。未来需要进行随机对照试验,以评估DSI在临床护理中的实施可行性和有效性。